Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Small Cell Lung Cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Treatment
1525 results:

  • 1. Suppression of NSCLC progression via the co-administration of Danusertib, an AURK inhibitor, and KRIBB11, an HSF1 inhibitor.
    Zhang X; Lei Y; Chen X; He J; Liu Z; Zhu W; Xu Y; Jin X
    Biochem Pharmacol; 2024 May; 223():116155. PubMed ID: 38521474
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by akt inhibition.
    Deben C; Boullosa LF; Fortes FR; De La Hoz EC; Le Compte M; Seghers S; Peeters M; Vanlanduit S; Lin A; Dijkstra KK; Van Schil P; Hendriks JMH; Prenen H; Roeyen G; Lardon F; Smits E
    J Exp Clin Cancer Res; 2024 Mar; 43(1):88. PubMed ID: 38515178
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. [Demethylzeylasteral inhibits proliferation, migration and invasion and promotes apoptosis of non-small cell lung cancer cells by inhibiting the akt/CREB signaling pathway].
    Han Q; Ye M; Jin Q
    Nan Fang Yi Ke Da Xue Xue Bao; 2024 Feb; 44(2):280-288. PubMed ID: 38501413
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Single-cell transcriptomic sequencing data reveal aberrant DNA methylation in SMAD3 promoter region in tumor-associated fibroblasts affecting molecular mechanism of radiosensitivity in non-small cell lung cancer.
    Han F; Chen S; Zhang K; Zhang K; Wang M; Wang P
    J Transl Med; 2024 Mar; 22(1):288. PubMed ID: 38493128
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Metformin and buparlisib synergistically induce apoptosis of non-small lung cancer (NSCLC) cells via akt/FoxO3a/Puma axis.
    Shanshan W; Hongying M; Jingjing F; Rui Y
    Toxicol In Vitro; 2024 May; 97():105801. PubMed ID: 38479708
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Anlotinib Inhibits Cisplatin Resistance in Non-small-cell lung cancer cells by Inhibiting MCL-1 Expression via MET/STAT3/akt Pathway.
    Wang L; Xu L; Han S; Zhu X
    Can Respir J; 2024; 2024():2632014. PubMed ID: 38468814
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Corynoxine triggers cell death via activating PP2A and regulating akt-mTOR/GSK3β axes in NSCLC.
    Hou G; Hu W; Sang Y; Gan X; Xu H; Hu Q; Cao X
    Biochem Pharmacol; 2024 Apr; 222():116110. PubMed ID: 38460908
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities.
    Liu X; Mei W; Zhang P; Zeng C
    Pharmacol Res; 2024 Apr; 202():107123. PubMed ID: 38432445
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Synergistic anti-tumor effects of lenalidomide and gefitinib by upregulating ADRB2 and inactivating the mTOR/PI3K/akt signaling pathway in lung adenocarcinoma.
    Zhou S; Deng M; Bian X; Shi J; Liang R; Tao M
    Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):120-127. PubMed ID: 38430032
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Exploration of Ginkgo biloba leaves on non-small cell lung cancer based on network pharmacology and molecular docking.
    Wang M; Li R; Bai M; Zhou X
    Medicine (Baltimore); 2024 Mar; 103(9):e37218. PubMed ID: 38428907
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Modulation of cellular metabolism and alleviation of bacterial dysbiosis by Aconiti Lateralis Radix Praeparata in non-small cell lung cancer treatment.
    Zhang W; Ding M; Feng Y; Cai S; Luo Z; Shan J; Di L
    Phytomedicine; 2024 Apr; 126():155099. PubMed ID: 38412665
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. [Mechanism of n-butanol fraction of Wenxia Formula combining with gefitinib in treating non-small cell lung cancer based on network pharmacology and in vitro experiment].
    Chen RJ; Bi QY; Shi JM; Zhong J; Han JT; Ji XM
    Zhongguo Zhong Yao Za Zhi; 2024 Jan; 49(2):471-486. PubMed ID: 38403323
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy.
    Raskova Kafkova L; Mierzwicka JM; Chakraborty P; Jakubec P; Fischer O; Skarda J; Maly P; Raska M
    Front Immunol; 2024; 15():1342086. PubMed ID: 38384472
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Lineage-specific intolerance to oncogenic drivers restricts histological transformation.
    Gardner EE; Earlie EM; Li K; Thomas J; Hubisz MJ; Stein BD; Zhang C; Cantley LC; Laughney AM; Varmus H
    Science; 2024 Feb; 383(6683):eadj1415. PubMed ID: 38330136
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. CD36 inhibition reduces non-small-cell lung cancer development through akt-mTOR pathway.
    Liu H; Guo W; Wang T; Cao P; Zou T; Peng Y; Yan T; Liao C; Li Q; Duan Y; Han J; Zhang B; Chen Y; Zhao D; Yang X
    Cell Biol Toxicol; 2024 Feb; 40(1):10. PubMed ID: 38319449
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Network pharmacology study to explore the multiple molecular mechanism of SH003 in the treatment of non-small cell lung cancer.
    Lee K; Choi YJ; Lim HI; Cho KJ; Kang N; Ko SG
    BMC Complement Med Ther; 2024 Feb; 24(1):70. PubMed ID: 38303001
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Plin2 inhibits autophagy via activating akt/mTOR pathway in non-small cell lung cancer.
    Wang Y; Hu Y; Xu R; Jin X; Jiao W
    Exp Cell Res; 2024 Feb; 435(2):113955. PubMed ID: 38301990
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Ginsenoside Rg5 induces NSCLC cell apoptosis and autophagy through PI3K/akt/mTOR signaling pathway.
    Zhang C; Jin Y
    Hum Exp Toxicol; 2024; 43():9603271241229140. PubMed ID: 38289222
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Amplifying T cell-mediated antitumor immune responses in nonsmall cell lung cancer through photodynamic therapy and anti-PD1.
    Gong B; Wang L; Zhang H; Wang Q; Li W
    Cell Biochem Funct; 2024 Jan; 42(1):e3925. PubMed ID: 38269509
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Integrating network pharmacology and experimental verification to investigate the pharmacological mechanisms of Buzhong Yiqi decoction in the treatment of non-small cell lung cancer.
    Zeng P; Wang F; Zhang J; Ur Rashid H; Li X; Zhang P; Luo Y; Wu X
    Chem Biol Drug Des; 2024 Jan; 103(1):e14414. PubMed ID: 38230796
    [TBL] [Abstract] [Full Text] [Related]  


    of 77.